[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

BG103671A - Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes - Google Patents

Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes

Info

Publication number
BG103671A
BG103671A BG103671A BG10367199A BG103671A BG 103671 A BG103671 A BG 103671A BG 103671 A BG103671 A BG 103671A BG 10367199 A BG10367199 A BG 10367199A BG 103671 A BG103671 A BG 103671A
Authority
BG
Bulgaria
Prior art keywords
sulphonylcarbamide
glytazone
combinations
treatment
diabetes
Prior art date
Application number
BG103671A
Other languages
Bulgarian (bg)
English (en)
Inventor
Randall WHITCOMB
Original Assignee
Warner-Lambert Company Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner-Lambert Company Llc filed Critical Warner-Lambert Company Llc
Publication of BG103671A publication Critical patent/BG103671A/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BG103671A 1997-02-19 1999-08-19 Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes BG103671A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3822497P 1997-02-19 1997-02-19
PCT/US1997/021996 WO1998036755A1 (en) 1997-02-19 1997-12-01 Sulfonylurea-glitazone synergistic combinations for diabetes

Publications (1)

Publication Number Publication Date
BG103671A true BG103671A (en) 2000-04-28

Family

ID=21898725

Family Applications (1)

Application Number Title Priority Date Filing Date
BG103671A BG103671A (en) 1997-02-19 1999-08-19 Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes

Country Status (29)

Country Link
US (2) US5859037A (ja)
EP (1) EP0957923A1 (ja)
JP (1) JP2001512478A (ja)
KR (1) KR20000071179A (ja)
CN (1) CN1244801A (ja)
AR (1) AR011829A1 (ja)
AU (1) AU741215B2 (ja)
BG (1) BG103671A (ja)
BR (1) BR9714505A (ja)
CA (1) CA2272478A1 (ja)
CZ (1) CZ289299A3 (ja)
EA (1) EA199900725A1 (ja)
EE (1) EE9900345A (ja)
GT (1) GT199800037A (ja)
HN (1) HN1997000167A (ja)
HU (1) HUP0001528A3 (ja)
IL (1) IL130027A (ja)
IS (1) IS5058A (ja)
NO (1) NO993982D0 (ja)
NZ (1) NZ336002A (ja)
PA (1) PA8447401A1 (ja)
PE (1) PE74399A1 (ja)
PL (1) PL335166A1 (ja)
SK (1) SK111899A3 (ja)
SV (1) SV1998000010A (ja)
TR (1) TR199902033T2 (ja)
UY (1) UY24893A1 (ja)
WO (1) WO1998036755A1 (ja)
ZA (1) ZA981343B (ja)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes
PL195140B1 (pl) * 1997-06-18 2007-08-31 Smithkline Beecham Plc Kompozycja farmaceutyczna zawierająca 5-[4-[2-(N-metylo-N-(2-pirydylo)amino)etoksy]-benzylo] tiazolidyno-2,4-dion i jej zastosowanie
US20020004515A1 (en) * 1997-06-18 2002-01-10 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and metformin
US20010049380A1 (en) * 1997-06-18 2001-12-06 Smith Stephen Alistair Treatment of diabetes with thiazolidinedione and sulphonylurea
PL198018B1 (pl) * 1997-06-18 2008-05-30 Smithkline Beecham Plc Kompozycja farmaceutyczna przeciwcukrzycowa zawierająca sulfonylomocznik i tiazolidynodion i jej zastosowanie
GB9715306D0 (en) * 1997-07-18 1997-09-24 Smithkline Beecham Plc Novel method of treatment
US6099859A (en) 1998-03-20 2000-08-08 Andrx Pharmaceuticals, Inc. Controlled release oral tablet having a unitary core
US7105552B2 (en) 1998-05-08 2006-09-12 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
EP1087963B1 (en) 1998-06-19 2004-08-25 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US7045519B2 (en) * 1998-06-19 2006-05-16 Chiron Corporation Inhibitors of glycogen synthase kinase 3
US20030153607A1 (en) * 1998-11-12 2003-08-14 Smithkline Beecham P.L.C. Novel composition and use
GB9824893D0 (en) * 1998-11-12 1999-01-06 Smithkline Beckman Corp Novel method of treatment
US20040081697A1 (en) * 1998-11-12 2004-04-29 Smithkline Beecham P.L.C. Pharmaceutical composition for modified release of an insulin sensitiser and another antidiabetic agent
US20040102486A1 (en) * 1998-11-12 2004-05-27 Smithkline Beecham Corporation Novel method of treatment
NZ512219A (en) * 1998-12-24 2004-12-24 Metabasis Therapeutics Inc A combination of FBPase inhibitors and insulin sensitizers for the treatment of diabetes
US7001746B1 (en) * 1999-01-29 2006-02-21 Artecel Sciences, Inc. Methods and compositions for the differentiation of human preadipocytes into adipocytes
US6617122B1 (en) * 1999-03-15 2003-09-09 Xenon Genetics, Inc. Process for identifying modulators of ABC1 activity
US7407978B2 (en) * 1999-04-06 2008-08-05 Theracos, Inc. Heterocyclic analogs of diphenylethylene compounds
US20060154864A1 (en) * 1999-11-01 2006-07-13 Emory University Transcript factor and an Akt substrate related to transcriptional action of insulin and applications of same
US7563775B2 (en) * 2000-11-01 2009-07-21 Betty C. Villafuerte Insulin-responsive DNA binding protein-1 and methods to regulate insulin-responsive genes
FR2802814B1 (fr) * 1999-12-23 2002-02-22 Aventis Pharma Sa Association de deoxyfructosazine et d'un antidiabetique de la famille des sulfonylurees
EP1145717B1 (en) 2000-04-13 2004-05-12 Pfizer Products Inc. Synergistic effect of glyburide and milrinone
GB0014969D0 (en) * 2000-06-19 2000-08-09 Smithkline Beecham Plc Novel method of treatment
KR200249057Y1 (ko) * 2001-03-22 2001-10-19 김진환 뚜껑, 받침대에 합체된 하수역류. 악취방지 장치
US6492339B1 (en) 2001-05-23 2002-12-10 Insmed, Incorporated Compositions comprising D-chiro inositol and sulfonylureas and methods of treatment thereof
SE0101982D0 (sv) * 2001-06-01 2001-06-01 Astrazeneca Ab Pharmaceutical combination
US7785627B2 (en) * 2002-09-20 2010-08-31 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US9060941B2 (en) * 2002-09-20 2015-06-23 Actavis, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
CN100544717C (zh) 2002-09-20 2009-09-30 华生制药公司 含有双胍和噻唑烷二酮衍生物的药物剂型
US7959946B2 (en) 2002-09-20 2011-06-14 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US8084058B2 (en) 2002-09-20 2011-12-27 Watson Pharmaceuticals, Inc. Pharmaceutical formulation containing a biguanide and a thiazolidinedione derivative
US20040147564A1 (en) * 2003-01-29 2004-07-29 Rao Vinay U. Combinations of glimepiride and the thiazolidinedione for treatment of diabetes
ES2556244T3 (es) 2003-10-31 2016-01-14 Takeda Pharmaceutical Company Limited Preparación sólida que comprende pioglitazona, glimepirida y un éster de ácido graso de polioxietilensorbitán
MXPA04009236A (es) * 2004-09-23 2006-03-27 Jorge Luis Rosado Loria Composicion sinergistica para el tratamiento de diabetes y sus comorbilidades.
WO2006074278A2 (en) * 2005-01-05 2006-07-13 Mitsunori Ono Compositions for treating diabetes or obesity
TW200722088A (en) * 2005-05-27 2007-06-16 Sankyo Co Diabetes remedy
EP1937716A2 (en) * 2005-09-08 2008-07-02 Uutech Limited Analogs of gastric inhibitory polypeptide as a treatment for age related decreased pancreatic beta cell function
US20090170762A1 (en) * 2005-09-08 2009-07-02 Uutech Limited Treatment of Diabetes Related Obesity
WO2007059372A2 (en) * 2005-11-09 2007-05-24 St. Jude Children's Research Hospital Use of chloroquine to treat metabolic syndrome
MXPA05013220A (es) * 2005-12-06 2007-06-05 Leopoldo De Jesus Espinosa Abdala Composiciones farmaceuticas que comprenden sustancias antidiabeticas combinadas para su uso en diabetes mellitus tipo 2.
ES2576258T3 (es) 2005-12-22 2016-07-06 Takeda Pharmaceutical Company Limited Preparación sólida que contiene un sensibilizador de insulina
TW200816995A (en) * 2006-08-31 2008-04-16 Daiichi Sankyo Co Ltd Pharmaceutical composition containing insulin sensitizers
AU2008232937B2 (en) 2007-03-30 2012-09-27 Ambrx, Inc. Modified FGF-21 polypeptides and their uses
JP5812318B2 (ja) 2007-12-04 2015-11-11 レメディー ファーマシューティカルズ， インコーポレイテッド 凍結乾燥のための改良された処方物および方法ならびにそれによって提供される凍結乾燥物
FR2928836B1 (fr) * 2008-03-21 2011-08-26 Servier Lab Forme galenique secable permettant une liberation modifiee du principe actif
KR20200022525A (ko) * 2008-12-04 2020-03-03 충시 위 고투과력을 가진 조성물 및 이의 적용
US20110065756A1 (en) * 2009-09-17 2011-03-17 De Taeye Bart M Methods and compositions for treatment of obesity-related diseases
CN102655866B (zh) * 2009-11-13 2013-11-13 东丽株式会社 糖尿病的治疗或预防药
EP2575826B1 (en) 2010-05-24 2019-07-17 Ozstar Therapeutics Pty Ltd Anti-diabetic compositions
EP4282363A3 (en) 2011-01-19 2024-01-10 Fractyl Health, Inc. Devices for the treatment of tissue
JP2014533702A (ja) * 2011-11-23 2014-12-15 オージースター セラピューティクス プロプライアタリ リミテッド 改良された相乗作用抗糖尿病組成物
CN103159651B (zh) * 2011-12-14 2015-06-17 安徽贝克联合制药有限公司 磺酰脲胍及其制备方法和用途
WO2015077571A1 (en) 2013-11-22 2015-05-28 Fractyl Laboratories, Inc. Systems, devices and methods for the creation of a therapeutic restriction in the gastrointestinal tract
IL296643B1 (en) 2012-02-27 2024-11-01 Fractyl Health Inc Heat excision systems, devices and methods for tissue treatment
WO2013159066A1 (en) 2012-04-19 2013-10-24 Fractyl Laboratories, Inc. Tissue expansion devices, system and methods
EP2879605A4 (en) 2012-07-30 2016-04-06 Fractyl Lab Inc ELECTRICITY CONTROL SYSTEMS, DEVICES AND METHOD FOR TREATMENT OF TISSUE
WO2014026055A1 (en) 2012-08-09 2014-02-13 Fractyl Laboratories Inc. Ablation systems, devices and methods for the treatment of tissue
EP2903626A4 (en) 2012-10-05 2016-10-19 Fractyl Lab Inc METHODS, SYSTEMS AND DEVICES FOR CARRYING OUT MULTIPLE TREATMENTS OF A PATIENT
WO2014197632A2 (en) 2013-06-04 2014-12-11 Fractyl Laboratories, Inc. Methods, systems and devices for reducing the luminal surface area of the gastrointestinal tract
WO2015038973A1 (en) 2013-09-12 2015-03-19 Fractyl Laboratories, Inc. Systems, methods and devices for treatment of target tissue
US10959774B2 (en) 2014-03-24 2021-03-30 Fractyl Laboratories, Inc. Injectate delivery devices, systems and methods
US11185367B2 (en) 2014-07-16 2021-11-30 Fractyl Health, Inc. Methods and systems for treating diabetes and related diseases and disorders
US9757535B2 (en) 2014-07-16 2017-09-12 Fractyl Laboratories, Inc. Systems, devices and methods for performing medical procedures in the intestine
EP3169260B1 (en) 2014-07-16 2019-09-25 Fractyl Laboratories, Inc. System for treating diabetes and related diseases and disorders
PE20170950A1 (es) 2014-10-24 2017-07-13 Bristol Myers Squibb Co Polipeptidos del factor de crecimiento de fibroblastos 2 (fgf-21) modificados y usos de los mismos
CN108079000A (zh) * 2018-02-01 2018-05-29 湖南博隽生物医药有限公司 一种治疗糖尿病的药物组合物及其制备方法
WO2021102423A1 (en) * 2019-11-22 2021-05-27 Brown University Compositions and methods for treating, preventing or reversing age-associated inflammation and disorders

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5917052A (en) * 1994-09-28 1999-06-29 Shaman Pharmaceuticals, Inc. Hypoglycemic agent from cryptolepis
TW438587B (en) * 1995-06-20 2001-06-07 Takeda Chemical Industries Ltd A pharmaceutical composition for prophylaxis and treatment of diabetes
NO318765B1 (no) * 1995-07-03 2005-05-02 Sankyo Co Anvendelse av en HMG-CoA reduktaseinhibitor og en insulinsensibilisator til fremstilling av et medikament for forebyggelse eller behandling av arteriosklerose eller xantom, samt pakket farmasoytisk preparat som omfatter de to midlene i separate porsjoner.
US5859037A (en) * 1997-02-19 1999-01-12 Warner-Lambert Company Sulfonylurea-glitazone combinations for diabetes

Also Published As

Publication number Publication date
CA2272478A1 (en) 1998-08-27
BR9714505A (pt) 2000-03-21
AU741215B2 (en) 2001-11-29
PE74399A1 (es) 1999-08-20
US5972973A (en) 1999-10-26
EP0957923A1 (en) 1999-11-24
HN1997000167A (es) 1999-02-09
US5859037A (en) 1999-01-12
HUP0001528A3 (en) 2000-12-28
PL335166A1 (en) 2000-04-10
IL130027A0 (en) 2000-02-29
KR20000071179A (ko) 2000-11-25
GT199800037A (es) 1999-08-12
HUP0001528A2 (hu) 2000-11-28
IS5058A (is) 1999-05-27
UY24893A1 (es) 1998-07-10
IL130027A (en) 2005-09-25
AR011829A1 (es) 2000-09-13
CZ289299A3 (cs) 1999-11-17
EE9900345A (et) 2000-02-15
ZA981343B (en) 1998-11-16
WO1998036755A1 (en) 1998-08-27
CN1244801A (zh) 2000-02-16
EA199900725A1 (ru) 2000-04-24
PA8447401A1 (es) 2001-12-14
SV1998000010A (es) 1999-02-02
NZ336002A (en) 2002-03-28
AU5590898A (en) 1998-09-09
JP2001512478A (ja) 2001-08-21
TR199902033T2 (xx) 2000-02-21
SK111899A3 (en) 2000-09-12
NO993982L (no) 1999-08-18
NO993982D0 (no) 1999-08-18

Similar Documents

Publication Publication Date Title
BG103671A (en) Combinations of sulphonylcarbamide-glytazone having synergetic effect for the treatment of diabetes
MXPA03003870A (es) Terapia de combinacion que comprende agentes antidiabeticos y anticonvulsionantes.
AU4714393A (en) Use of 1,3-dicyclopropymethyl-8-amino-xanthine for the treatment and prevention of type ii diabetes mellitus and obesity
HK1022701A1 (en) Exendin analogues, processes for their preparationand medicaments containing them exendin.
AU1450900A (en) Methods of treatment of type 2 diabetes
AP2000001929A0 (en) Substituted indolealkanoic acids.
ZA989560B (en) Compositions containing an Ó 1,2-fucose linkage and uses thereof.
BG102644A (en) Improved concentrated inoculation and infusion solutions for intravasal application
ZA953336B (en) Substituted sulfonamides as selective B3 agonists for the treatment of diabetes and obesity
ZA964298B (en) Use of aryl-substituted cyclobutylalkylamines for the treatment of obesity.
BG102250A (en) The use of marigold-extracted glycosides for the treatment of psoriasis
EP0612513A3 (en) External skin treatment composition.
HK1003051A1 (en) Treatment and prophylaxis of pancreatitis
IL142220A0 (en) Method of treating viral hemorrhagic fever
EP0674001A3 (en) New protease to treat dead tissue.
EP0999848A4 (en) CHIMEAN PROTEINS FOR TREATING DIABETES
HU9503453D0 (en) Heterocyclic chemistry
EP1251847A4 (en) NEW USE OF PRODIGIOSIN FOR THE TREATMENT OF DIABETES MELLITUS
EP0671500A3 (en) Compositions for the treatment of textiles.
IL139303A0 (en) Treatment of arthritis and other similar conditions
AU2002257598A1 (en) Agent for treating diabetes mellitus
EP0667373A3 (en) Stabilization of fluorosilicone elastomers.
ZA947333B (en) Treatment of titaniferous material.
WO1998006431A3 (en) Method for treating diabetes
ZA971217B (en) Diamond treatment.